Mechanisms and risk factors of thrombosis in cancer
Introduction
Cancer patients may present many types of hemostatic disorders that significantly contribute to morbidity and mortality in this disease. A tight relationship exists between malignant disease, the occurrence of coagulation abnormalities and thrombosis. The relationship relies on the evidence that cancer induces a prothrombotic switch of the host hemostatic system, and in turn, blood clotting activation stimulates tumor growth and dissemination.
Cancer is associated with a four- to seven-fold increase in the risk of venous thromboembolism (VTE). However, even without thrombosis, the majority of cancer patients present with hemostatic alterations detectable by laboratory tests, which reveal different degrees of coagulation activation and characterize the hypercoagulable state of these subjects (Falanga and Russo, 2012).
Currently, it is fully recognized that cancer patients are at significant risk of developing thrombotic events, spanning from venous or arterial thrombosis to systemic syndromes, such as disseminated intravascular coagulation (DIC) with severe bleeding. Preventing these complications is clinically relevant because they considerably contribute to the morbidity and mortality of these patients (Falanga et al., 2014).
The pathogenesis of the cancer-associated coagulopathy is complex and multifactorial. Most importantly, tumor cells gain the capacity to activate the host hemostatic system, and this phenomenon is driven by the same oncogenes responsible for the cellular neoplastic transformation. By this process, cancer tissues become capable to express different procoagulant proteins (i.e. Tissue Factor [TF], Cancer Procoagulant [CP], Factor VII), which contribute to the occurrence of the overt symptomatic coagulopathy in vivo (Magnus et al., 2014a). The shedding of procoagulant microparticles [MPs] is also regulated by oncogenic events and further adds to the pathogenesis of the cancer-associated hypercoagulable state. Finally, the changes in the stromal cells of the tumor “niche” induced by tumor TF provide new evidence of the influence of the hemostasis system on cancer development.
To the other hand, many clinical factors influence the thrombotic risk of cancer patients, who definitely represent a high-risk category. Clinical factors include general cardiovascular risk factors, cancer specific risk factors, and anti-cancer therapies. Recent data confirm that the risk of developing VTE is increased up to seven-fold in these patients as compared to the general population (Timp et al., 2013). To help clinicians in the prevention and management of thrombotic events in cancer patients, a number of guidelines have been released from national and international scientific societies (Lyman et al., 2015).
This paper wishes to provide the most recent discoveries on the coagulopathy of cancer patients, the mechanisms underlying this phenomenon, and the risk assessment to predict thrombosis in the single patient.
Section snippets
Pathogenesis of cancer-associated thrombosis
The molecular and laboratory features of cancer-associated thrombosis are difficult to assess clinically; therefore, the weight of each of these factors on the overall thrombotic risk of the single patient is unknown at this time. The principal mechanisms of cancer-associated thrombosis include the expression of hemostatic proteins by tumor cells, the production of microparticles, inflammatory cytokines (i.e., tumor necrosis factor-alpha, interleukin-1b), and proangiogenic factors (vascular
Risk factors and risk assessment in cancer patients
Multiple clinical risk factors, i.e., patient-related or cancer-specific, concur to the activation of blood coagulation and importantly contribute to the thrombotic risk of cancer patients (Table 1) (Khorana and McCrae, 2014, Falanga et al., 2015b).
The clinical thrombotic risk factors, together with the biological procoagulant mechanisms expressed by cancer tissues, contribute to the occurrence of the procoagulant shift in the hemostatic balance of patients with cancer. Indeed, subclinical
Assessment of the thrombotic risk in cancer patients
Recently, the approach to risk assessment for thrombosis in cancer patients relies on the development of “risk assessment models” (RAM). The first was developed by Khorana specifically for cancer patients undergoing chemotherapy (Khorana et al., 2008). This RAM is based on five predictive variables, including cancer site, platelet count, hemoglobin level or the use of erythropoiesis-stimulating agents, leukocyte count, and body mass index. This model using a simple scoring system, is based on
Conclusions
Cancer is associated with an imbalance in the hemostatic system, which predisposes to thrombotic complications. Several procoagulant molecules, among which TF is the most important, are expressed by cancer cells or are induced by cancer cell in normal vascular tissues by both the release of soluble mediators and the direct cancer cell–host cell contact. TF exposure by endothelial cell, leukocyte, or circulating MPs of different origins plays a very important role. A very important advance in
Conflicts of interest
There are no conflicts of interest.
Acknowledgments
The authors wish to thank the Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.), grants “IG2013” n. 14505 and “5 per mille” n. ED12237, for its support.
References (47)
- et al.
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)
Blood
(2008) - et al.
Prediction of venous thromboembolism in cancer patients
Blood
(2010) - et al.
Thrombophilia and risk of venous thrombosis in patients with cancer
Thromb. Res.
(2007) - et al.
Microvesicle-associated tissue factor and Trousseau's syndrome
J. Thromb. Haemost.
(2007) - et al.
Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis
J. Thromb. Haemost.
(2013) - et al.
Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid
Blood
(1995) - et al.
Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells
Blood
(1998) - et al.
Microparticles in tumor progression
Thromb. Res.
(2012) - et al.
Coagulation and cancer: biological and clinical aspects
J. Thromb. Haemost.
(2013) - et al.
The mechanisms of cancer-associated thrombosis
Thromb. Res.
(2015)
Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor
J. Biol. Chem.
Development and validation of a predictive model for chemotherapy-associated thrombosis
Blood
Risk stratification strategies for cancer-associated thrombosis: an update
Thromb. Res.
Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor
Eur. J. Cancer
The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia
Leuk. Res.
Oncogenes and the coagulation system--forces that modulate dormant and aggressive states in cancer
Thromb. Res.
Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’
Ann. Oncol.
Heparanase procoagulant activity in cancer progression
Thromb. Res.
Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells
Blood
Molecular basis for the relationship between thrombosis and cancer
Thromb. Res.
Mechanistic explanation for platelet contribution to cancer metastasis
Thromb. Res.
Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients
Thromb. Res.
Epidemiology of cancer-associated venous thrombosis
Blood
Cited by (174)
Preoperative Management of the Adult Oncology Patient
2024, Anesthesiology ClinicsPredictors of cancer in patients with acute pulmonary embolism
2023, Thrombosis ResearchUtility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohort
2023, Journal of Thrombosis and HaemostasisThrombosis and cachexia in cancer: Two partners in crime?
2023, Critical Reviews in Oncology/HematologyVenous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
2023, Annals of OncologyFactor VIII as a Novel Biomarker for Diagnosis, Prognosis, and Therapy Prediction in Human Cancer and Other Disorders
2024, Avicenna Journal of Medical Biotechnology